Parisa Hajjari, Malin Huldt Oldmark, Elisabeth Fernell, Klara Jakobsson, Ingrid Vinsa, Max Thorsson, Mehran Monemi, Lotta Stenlund, Anders Fasth, Catrin Furuhjelm, Jakob Åsberg Johnels, Christopher Gillberg, Mats Johnson
BACKGROUND: Treatment with intravenous immunoglobulin (IVIG) in children with Paediatric Acute-onset Neuropsychiatric Syndrome (PANS) has for many years been used on clinical indications, but the research evidence for its efficacy is insufficient. METHODS: Open-label prospective in-depth trial including ten children (median age 10.3 years) with PANS, who received IVIG treatment 2 g/kg monthly for three months. Primary outcomes were changes in symptom severity and impairment from baseline to first and second follow-up visits one month after first and one month after third treatment, using three investigator-rated scales: Paediatric Acute Neuropsychiatric Symptom (PANS) scale, Clinical Global Impression - Severity and Improvement (CGI-S and CGI-I) scales...
August 6, 2022: BMC Psychiatry